Resources
Insights on nuclear medicine and radiopharmaceuticals
Scientific publications and market data on a fast-growing field.
Publications
Selected articles
A selection of articles, editorials and reviews on radiopharmaceutical production, supply and market, by Protherium co-founder Richard Zimmermann.
- 2026View report
Nuclear Medicine series
MEDraysintellA reference report of more than 4,900 pages, divided into 3 volumes:Vol I: Current Landscape of the Nuclear Medicine MarketVol II: Strategic Landscape of Clinical Radiopharmaceutical DevelopmentVol III: Preclinical Landscape for Next-generation Radiopharmaceuticals - 2026View article
The Supply Chain Conundrum
Zimmermann RJournal of Nuclear Medicine, 2026 · Supplement on theranostics - 2026View article
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions — Part 2
Somma C, Zimmermann R, Gericke G, Herrmann KJournal of Nuclear Medicine, 2026 - 2026View article
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions — Part 1
Somma C, Zimmermann R, Gericke G, Herrmann KJournal of Nuclear Medicine, 2026 - 2025View article
Stakeholders of Theranostics
Zimmermann R, Beyer TJournal of Nuclear Medicine, 2025 · Discussion - 2025View article
Is 211At Really Happening?
Zimmermann RJournal of Nuclear Medicine, 2025 · Editorial - 2025View article
Green Nuclear Medicine and Radiotheranostics
Veit-Haibach P, Herrmann K, Zimmermann R, Hustinx RJournal of Nuclear Medicine, 2025 · State of the art - 2025View article
Radiotheranostics in a Crystal Ball
Zimmermann RRadiotheranostics Today (Oncidium Foundation), 20 February 2025 · Education - 2024View article
Radiotheranostics Global Market and Future Developments
Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann KSeminars in Nuclear Medicine, 2024 · Review - 2024View article
Production and regulatory issues for theranostics
Giammarile F, Paez D, Zimmermann R, et al.The Lancet Oncology — Theranostics 3, 2024 · Review - 2024View article
Actinium-225 Production and the Future Needs for Labeled Drugs
Zimmermann RRadiotheranostics Today (Oncidium Foundation), 6 March 2024 · Education - 2023View article
Is Actinium Really Happening?
Zimmermann RJournal of Nuclear Medicine, 2023 · Editorial - 2013View article
Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals
Zimmermann RGNuclear Medicine and Biology, 2013 · Review - 2008View article
Industrial Constraints in the Selection of Radionuclides and the Development of New Radiopharmaceuticals
Zimmermann RGJanuary 2008
Market evolution
A fast-growing market
Over the past decade, the nuclear medicine industry has experienced remarkable growth, with more than $53 billion invested in research and development. Over 190 molecules are currently in development, some of which have already reached the market.
This growth is creating a major need for production capacity: more than 30 dedicated radiopharmaceutical sites will be required in Europe by 2035. Market revenue is forecast to reach $44.1 billion by 2035.
$53B+Invested in R&D over the past decade
190+Molecules currently in development
30+Dedicated production sites needed in Europe by 2035
$44.1BForecast revenue by 2035
Source: MEDraysintell 2026
Looking for production capacity in Europe?
Discover how Protherium supports your project, from process transfer to commercial production.
